Literature DB >> 9620772

The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate.

C McCormick1, Y Leduc, D Martindale, K Mattison, L E Esford, A P Dyer, F Tufaro.   

Abstract

Hereditary multiple exostoses (HME) is an autosomal dominant disorder characterized by the formation of cartilage-capped tumours (exostoses) that develop from the growth plate of endochondral bone. This condition can lead to skeletal abnormalities, short stature and malignant transformation of exostoses to chondrosarcomas or osteosarcomas. Linkage analyses have identified three different genes for HME, EXT1 on 8q24.1, EXT2 on 11p11-13 and EXT3 on 19p (refs 6-9). Most HME cases have been attributed to missense or frameshift mutations in these tumour-supressor genes, whose functions have remained obscure. Here, we show that EXT1 is an ER-resident type II transmembrane glycoprotein whose expression in cells results in the alteration of the synthesis and display of cell surface heparan sulfate glycosaminoglycans (GAGs). Two EXT1 variants containing aetiologic missense mutations failed to alter cell-surface glycosaminoglycans, despite retaining their ER-localization.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620772     DOI: 10.1038/514

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  101 in total

1.  The EXT1/EXT2 tumor suppressors: catalytic activities and role in heparan sulfate biosynthesis.

Authors:  C Senay; T Lind; K Muguruma; Y Tone; H Kitagawa; K Sugahara; K Lidholt; U Lindahl; M Kusche-Gullberg
Journal:  EMBO Rep       Date:  2000-09       Impact factor: 8.807

2.  Increased urine heparan and chondroitin sulphate excretion in patients with osteopetrosis.

Authors:  R D Steiner; M P Whyte; E Chang; J Hanks; C Mattes; H Senephansiri; K M Gibson
Journal:  J Inherit Metab Dis       Date:  2000-02       Impact factor: 4.982

3.  The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate.

Authors:  C McCormick; G Duncan; K T Goutsos; F Tufaro
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

4.  Enzyme interactions in heparan sulfate biosynthesis: uronosyl 5-epimerase and 2-O-sulfotransferase interact in vivo.

Authors:  M A Pinhal; B Smith; S Olson; J Aikawa; K Kimata; J D Esko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

Review 5.  Heparan sulfate proteoglycans: intricate molecules with intriguing functions.

Authors:  R V Iozzo
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 6.  Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry.

Authors:  D Shukla; P G Spear
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 7.  The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins.

Authors:  G Duncan; C McCormick; F Tufaro
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 8.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

9.  A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses.

Authors:  Kazu Matsumoto; Fumitoshi Irie; Susan Mackem; Yu Yamaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

10.  Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma.

Authors:  Yvonne M Schrage; Liesbeth Hameetman; Karoly Szuhai; Anne-Marie Cleton-Jansen; Antonie H M Taminiau; Pancras C W Hogendoorn; Judith V M G Bovée
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.